Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"The authors declare that there is no conflict of interest."
"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by the National Cancer Institute (NCI) which provided financial support for the research described in this manuscript. It was conducted through the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) and supported by the UM1CA186712 grant to Dr WC. Dr DQ was supported by the NIH T32 grant CA247815. This study is registered at ClinicalTrials.gov (NCT02474173)."
"Trial registration: Onalespib and paclitaxel in treating patients with advanced TNBC https://clinicaltrials.gov/ct2/show/NCT02474173."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025